<p>Alumis Inc.（纳斯达克代码：ALMS - 获取免费报告）在周四因内部人士买入活动上涨了 11.3%。该公司交易最高达到 7.48 美元，最后交易价格为 7.3150 美元。在交易过程中，约有 425,307 股易手，较平均每日交易量 701,087 股下降了 39%。该股票此前收盘价为 6.57 美元。</p>
<ul>
<li>3 只逆势上涨的生物制药股票</li>
</ul>
<p>具体来说，董事 Srinivas Akkaraju 在 11 月 19 日（星期三）的一笔交易中购买了 137,772 股 Alumis 股票。该股票的购买均价为每股 6.56 美元，总交易额为 903,784.32 美元。购买后，该董事直接持有 517,517 股公司股票，价值为 3,394,911.52 美元。这笔交易代表了他们持股比例的 36.28% 的增长。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，董事 Srinivas Akkaraju 在 11 月 18 日（星期二）又购买了 102,652 股该股票。该股票的购买均价为每股 6.05 美元，总交易额为 621,044.60 美元。完成购买后，该董事直接持有 379,745 股公司股票，价值约为 2,297,457.25 美元。这笔交易代表了他们持股比例的 37.05% 的增长。有关此次购买的更多细节可在官方 SEC 披露中找到。在相关消息中，董事 James B. Tananbaum 在 11 月 19 日（星期三）购买了 190,500 股公司的股票。该股票的购买均价为每股 6.56 美元，总价值为 1,249,680.00 美元。收购后，该董事持有 2,542,003 股公司股票，价值为 16,675,539.68 美元。这代表了他们持股比例的 8.10% 的增长。该收购已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。</p>
<h2>分析师评级变动</h2>
<p>ALMS 已成为多份研究分析师报告的主题。华尔街 Zen 在 11 月 15 日（星期六）的报告中将 Alumis 的股票评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 11 月 13 日（星期四）的研究报告中重新发布了对 Alumis 股票的 “卖出（d-）” 评级。HC Wainwright 在 8 月 14 日（星期四）的报告中重申了对 Alumis 的 “买入” 评级，并给出了 14.00 美元的目标价。富国银行在 7 月 25 日（星期五）的研究报告中开始覆盖 Alumis，给予 “增持” 评级和 17.00 美元的目标价。最后，摩根士丹利在 8 月 15 日（星期五）的研究报告中将 Alumis 的目标价从 23.00 美元下调至 22.00 美元，并对该公司设定了 “增持” 评级。六位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 19.20 美元。</p>
<p><strong>阅读我们关于 Alumis 的最新研究报告</strong></p>
<h2>Alumis 上涨 12.3%</h2>
<p>该公司的市值为 7.6796 亿美元，市盈率为-1.82，贝塔值为-1.33。该股票的 50 日移动平均线为 4.61 美元，200 日移动平均线为 4.23 美元。</p>
<p>Alumis（纳斯达克代码：ALMS - 获取免费报告）最近在 11 月 13 日（星期四）发布了季度财报。该公司报告季度每股收益（EPS）为-1.06 美元，低于分析师一致预期的-0.92 美元，差距为 0.14 美元。该公司季度收入为 207 万美元，而分析师预期为 314 万美元。分析师平均预测 Alumis Inc.在本年度将发布-8.51 的每股收益。</p>
<h2>Alumis 的机构交易</h2>
<p>几家机构投资者和对冲基金最近调整了对 ALMS 的持股。Orbimed Advisors LLC 在第二季度购买了 Alumis 的新股份，价值为 5,779,000 美元。Velan Capital Investment Management LP 在第二季度购买了 Alumis 的新股份，价值约为 4,863,000 美元。Woodline Partners LP 在第三季度将其在 Alumis 的持股增加了 809.7%。Woodline Partners LP 现在持有 1,751,150 股公司股票，价值为 6,987,000 美元，此前在上个季度又购买了 1,558,660 股。Samsara Biocapital LLC 在第二季度将其在 Alumis 的持股增加了 47.0%。Samsara Biocapital LLC 现在持有 4,801,370 股公司股票，价值为 14,404,000 美元，此前在上个季度又购买了 1,534,872 股。最后，Tybourne Capital Management HK Ltd.在第二季度购买了 Alumis 的新股份，价值约为 4,198,000 美元。</p>
<h2>关于 Alumis</h2>
<p>（获取免费报告）</p>
<p>我们的使命是通过用靶向疗法替代广泛的免疫抑制来显著改善患者的生活。我们的名字 Alumis 体现了我们启迪免疫学的使命，灵感来自法语 “allumer”（点亮）和拉丁语 “immunis”（免疫系统）。我们是一家临床阶段的生物制药公司，最初专注于开发我们的两种酪氨酸激酶 2（TYK2）抑制剂：ESK-001，一种我们正在开发的第二代抑制剂，旨在最大化靶向抑制并优化耐受性，以及 A-005，一种能够穿透中枢神经系统（CNS）的分子。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Alumis</li>
<li>投资旅游股票的好处</li>
<li>NVIDIA 刚刚证明 AI 热潮比任何人想象的都要大</li>
<li>纽约证券交易所的股票为投资者提供多种优质选择</li>
<li>为什么 Target 股票可能会继续下跌，尽管有 5% 的股息收益率</li>
<li>什么是股息收割策略，投资者如何从中获利？</li>
<li>特斯拉是否在为年末反弹做准备——还是崩溃？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Alumis 吗？</h2>
<p>在考虑 Alumis 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Alumis 并不在名单上。</p>
<p>虽然 Alumis 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ALMS

<p>Alumis Inc.（纳斯达克代码：ALMS）在内部人士购买活动后，其股票上涨了 11.3%。董事 Srinivas Akkaraju 购买了大量股份，使其持股增加了超过 36%。董事 James B. Tananbaum 也购买了股份，提升了他的持股比例 8.10%。尽管股票上涨，但分析师评级褒贬不一，部分分析师下调了评级，市场共识目标价为 19.20 美元。该公司最近的财报未能达到预期，几家机构投资者也调整了对 Alumis 的持股</p>

<p>Alumis Inc. (NASDAQ:ALMS - Get Free Report) rose 11.3% on Thursday following insider buying activity. The company traded as high as $7.48 and last traded at $7.3150. Approximately 425,307 shares changed hands during trading, a decline of 39% from the average daily volume of 701,087 shares. The stock had previously closed at $6.57.</p>
<div class="lb-trans"><p>Alumis Inc.（纳斯达克代码：ALMS - 获取免费报告）在周四因内部人士买入活动上涨了 11.3%。该公司交易最高达到 7.48 美元，最后交易价格为 7.3150 美元。在交易过程中，约有 425,307 股易手，较平均每日交易量 701,087 股下降了 39%。该股票此前收盘价为 6.57 美元。</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只逆势上涨的生物制药股票</li>
</ul>
</div><p>Specifically, Director Srinivas Akkaraju acquired 137,772 shares of Alumis stock in a transaction on Wednesday, November 19th. The stock was purchased at an average price of $6.56 per share, for a total transaction of $903,784.32. Following the purchase, the director directly owned 517,517 shares of the company's stock, valued at $3,394,911.52. This trade represents a 36.28% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Srinivas Akkaraju bought 102,652 shares of the stock in a transaction dated Tuesday, November 18th. The shares were acquired at an average price of $6.05 per share, for a total transaction of $621,044.60. Following the completion of the purchase, the director directly owned 379,745 shares in the company, valued at approximately $2,297,457.25. This trade represents a 37.05% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In related news, Director James B. Tananbaum purchased 190,500 shares of the business's stock in a transaction that occurred on Wednesday, November 19th. The shares were bought at an average cost of $6.56 per share, with a total value of $1,249,680.00. Following the acquisition, the director owned 2,542,003 shares of the company's stock, valued at $16,675,539.68. This represents a 8.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.</p>
<div class="lb-trans"><p>具体来说，董事 Srinivas Akkaraju 在 11 月 19 日（星期三）的一笔交易中购买了 137,772 股 Alumis 股票。该股票的购买均价为每股 6.56 美元，总交易额为 903,784.32 美元。购买后，该董事直接持有 517,517 股公司股票，价值为 3,394,911.52 美元。这笔交易代表了他们持股比例的 36.28% 的增长。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，董事 Srinivas Akkaraju 在 11 月 18 日（星期二）又购买了 102,652 股该股票。该股票的购买均价为每股 6.05 美元，总交易额为 621,044.60 美元。完成购买后，该董事直接持有 379,745 股公司股票，价值约为 2,297,457.25 美元。这笔交易代表了他们持股比例的 37.05% 的增长。有关此次购买的更多细节可在官方 SEC 披露中找到。在相关消息中，董事 James B. Tananbaum 在 11 月 19 日（星期三）购买了 190,500 股公司的股票。该股票的购买均价为每股 6.56 美元，总价值为 1,249,680.00 美元。收购后，该董事持有 2,542,003 股公司股票，价值为 16,675,539.68 美元。这代表了他们持股比例的 8.10% 的增长。该收购已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>ALMS has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of Alumis from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 15th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Alumis in a research report on Thursday, November 13th. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $14.00 price target on shares of Alumis in a report on Thursday, August 14th. Wells Fargo &amp; Company assumed coverage on Alumis in a research note on Friday, July 25th. They issued an &#34;overweight&#34; rating and a $17.00 target price on the stock. Finally, Morgan Stanley cut their price target on Alumis from $23.00 to $22.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, August 15th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $19.20.</p>
<div class="lb-trans"><p>ALMS 已成为多份研究分析师报告的主题。华尔街 Zen 在 11 月 15 日（星期六）的报告中将 Alumis 的股票评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 11 月 13 日（星期四）的研究报告中重新发布了对 Alumis 股票的 “卖出（d-）” 评级。HC Wainwright 在 8 月 14 日（星期四）的报告中重申了对 Alumis 的 “买入” 评级，并给出了 14.00 美元的目标价。富国银行在 7 月 25 日（星期五）的研究报告中开始覆盖 Alumis，给予 “增持” 评级和 17.00 美元的目标价。最后，摩根士丹利在 8 月 15 日（星期五）的研究报告中将 Alumis 的目标价从 23.00 美元下调至 22.00 美元，并对该公司设定了 “增持” 评级。六位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 19.20 美元。</p>
</div><p><strong>Read Our Latest Research Report on Alumis</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Alumis 的最新研究报告</strong></p>
</div><h2>Alumis Trading Up 12.3%</h2>
<div class="lb-trans"><h2>Alumis 上涨 12.3%</h2>
</div><p>The firm has a market cap of $767.96 million, a P/E ratio of -1.82 and a beta of -1.33. The stock's fifty day moving average is $4.61 and its two-hundred day moving average is $4.23.</p>
<div class="lb-trans"><p>该公司的市值为 7.6796 亿美元，市盈率为-1.82，贝塔值为-1.33。该股票的 50 日移动平均线为 4.61 美元，200 日移动平均线为 4.23 美元。</p>
</div><p>Alumis (NASDAQ:ALMS - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.14). The firm had revenue of $2.07 million for the quarter, compared to analysts' expectations of $3.14 million. On average, analysts forecast that Alumis Inc. will post -8.51 EPS for the current year.</p>
<div class="lb-trans"><p>Alumis（纳斯达克代码：ALMS - 获取免费报告）最近在 11 月 13 日（星期四）发布了季度财报。该公司报告季度每股收益（EPS）为-1.06 美元，低于分析师一致预期的-0.92 美元，差距为 0.14 美元。该公司季度收入为 207 万美元，而分析师预期为 314 万美元。分析师平均预测 Alumis Inc.在本年度将发布-8.51 的每股收益。</p>
</div><h2>Institutional Trading of Alumis</h2>
<div class="lb-trans"><h2>Alumis 的机构交易</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of ALMS. Orbimed Advisors LLC purchased a new stake in shares of Alumis during the 2nd quarter valued at $5,779,000. Velan Capital Investment Management LP purchased a new stake in Alumis during the second quarter valued at about $4,863,000. Woodline Partners LP lifted its stake in Alumis by 809.7% during the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company's stock worth $6,987,000 after purchasing an additional 1,558,660 shares during the last quarter. Samsara Biocapital LLC boosted its holdings in shares of Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company's stock worth $14,404,000 after purchasing an additional 1,534,872 shares in the last quarter. Finally, Tybourne Capital Management HK Ltd. purchased a new position in shares of Alumis during the 2nd quarter valued at about $4,198,000.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近调整了对 ALMS 的持股。Orbimed Advisors LLC 在第二季度购买了 Alumis 的新股份，价值为 5,779,000 美元。Velan Capital Investment Management LP 在第二季度购买了 Alumis 的新股份，价值约为 4,863,000 美元。Woodline Partners LP 在第三季度将其在 Alumis 的持股增加了 809.7%。Woodline Partners LP 现在持有 1,751,150 股公司股票，价值为 6,987,000 美元，此前在上个季度又购买了 1,558,660 股。Samsara Biocapital LLC 在第二季度将其在 Alumis 的持股增加了 47.0%。Samsara Biocapital LLC 现在持有 4,801,370 股公司股票，价值为 14,404,000 美元，此前在上个季度又购买了 1,534,872 股。最后，Tybourne Capital Management HK Ltd.在第二季度购买了 Alumis 的新股份，价值约为 4,198,000 美元。</p>
</div><h2>About Alumis</h2>
<div class="lb-trans"><h2>关于 Alumis</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words &#34;allumer&#34;-French for illuminate-and &#34;immunis&#34;-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.</p>
<div class="lb-trans"><p>我们的使命是通过用靶向疗法替代广泛的免疫抑制来显著改善患者的生活。我们的名字 Alumis 体现了我们启迪免疫学的使命，灵感来自法语 “allumer”（点亮）和拉丁语 “immunis”（免疫系统）。我们是一家临床阶段的生物制药公司，最初专注于开发我们的两种酪氨酸激酶 2（TYK2）抑制剂：ESK-001，一种我们正在开发的第二代抑制剂，旨在最大化靶向抑制并优化耐受性，以及 A-005，一种能够穿透中枢神经系统（CNS）的分子。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Alumis</li>
<li>Investing in Travel Stocks Benefits</li>
<li>NVIDIA Just Proved the AI Boom Is Bigger Than Anyone Thought</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Why Target Stock May Keep Falling Despite a 5% Dividend Yield</li>
<li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li>
<li>Is Tesla Setting Up for a Year-End Rebound—or a Collapse?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Alumis</li>
<li>投资旅游股票的好处</li>
<li>NVIDIA 刚刚证明 AI 热潮比任何人想象的都要大</li>
<li>纽约证券交易所的股票为投资者提供多种优质选择</li>
<li>为什么 Target 股票可能会继续下跌，尽管有 5% 的股息收益率</li>
<li>什么是股息收割策略，投资者如何从中获利？</li>
<li>特斯拉是否在为年末反弹做准备——还是崩溃？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Alumis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Alumis 吗？</h2>
</div><p>Before you consider Alumis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Alumis 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Alumis 并不在名单上。</p>
</div><p>While Alumis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Alumis 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Alumis（纳斯达克股票代码：ALMS）在内部人士买入活动后股价上涨 11.3%